These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31201151)

  • 21. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
    van Malderen K; Halawi H; Camilleri M
    Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
    Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K
    Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
    Lawson R; King F; Marsh K; Altincatal A; Cimen A
    Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxegol increases frequency of bowel movements and combats inadequate response to laxatives.
    Holzer P
    Evid Based Med; 2015 Feb; 20(1):5. PubMed ID: 25209526
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacological characterization of naloxegol: In vitro and in vivo studies.
    Costanzini A; Ruzza C; Neto JA; Sturaro C; Malfacini D; Sternini C; De Giorgio R; Calò G
    Eur J Pharmacol; 2021 Jul; 903():174132. PubMed ID: 33933466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
    Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
    CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
    Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
    Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naloxegol oxalate, pirfenidone, and nintedanib.
    Hussar DA; Jeon MM
    J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
    Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
    Leonard J; Baker DE
    Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naloxegol: A Review of Clinical Trials and Applications to Practice.
    Dume R; Shuman M
    Orthop Nurs; 2019; 38(3):209-211. PubMed ID: 31124873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periarticular Morphine-Induced Sphincter of Oddi Spasm Causing Severe Pain and Bradycardia in an Awake Patient Under Spinal Anesthesia: An Important Diagnostic Consideration.
    Koumpan Y; Engen D; Tanzola R; Saha T
    A A Case Rep; 2016 Oct; 7(7):152-4. PubMed ID: 27513967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
    Velosy B; Madácsy L; Lonovics J; Csernay L
    Eur J Gastroenterol Hepatol; 1997 Nov; 9(11):1109-12. PubMed ID: 9431903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in Recruiting Patients to a Controlled Feasibility Study of a Drug for Opioid-Induced Constipation: Lessons From the Population With Advanced Cancer.
    Bull J; Bonsignore L; Massie L; Riggs A; Knotkova H; Wellman C; Portenoy R
    J Pain Symptom Manage; 2019 May; 57(5):e5-e8. PubMed ID: 30853551
    [No Abstract]   [Full Text] [Related]  

  • 36. Cholangiographic demonstration of relief of narcotic-induced spasm of the sphincter of Oddi.
    McLean ER; Widmann WD; Small HS
    Am Surg; 1982 Mar; 48(3):134-6. PubMed ID: 7073136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent hiccups after slow-release morphine.
    Wilcox SK
    Palliat Med; 2005 Oct; 19(7):568-9. PubMed ID: 16295294
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating Opioid-Induced Constipation in Older Adults: New Options.
    Sani H; Mahan RJ
    Consult Pharm; 2015 Oct; 30(10):612-5. PubMed ID: 26450143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis.
    Cobo Dols M; Beato Zambrano C; Cabezón Gutiérrez L; Chicas Sett R; Blancas López-Barajas MI; García Navalón F; Fírvida Pérez JL; Serrano Bermúdez G; Togores Torres P; Delgado Mingorance I; Giraldo Marín A; Librán Oriol A; Paredes Lario A; Sánchez Mauriño P; Higuera Gómez O; Moreno Muñoz D; Jiménez López AJ; Huerta González I; Sanz Yagüe A; Soler López B
    BMJ Support Palliat Care; 2021 Mar; 11(1):25-31. PubMed ID: 32376758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of persistent opioid-induced constipation in patients with hematological malignancies: case report].
    Recenti Prog Med; 2018 Nov; 109(11):11e-14e. PubMed ID: 30565581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.